Rosiglitazone modulates collagen deposition and metabolism in atherosclerotic plaques of fatfed ApoEknockout mice

Author：

E-ISSN： 1792-1015|10|4|1265-1270

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.10, Iss.4, 2015-01, pp. : 1265-1270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Abnormal collagen deposition, as well as collagen metabolism, plays a crucial role in the formation and progression of vulnerable atherosclerotic plaques (VAPs), which are susceptible to rupture. According to our previous findings, rosiglitazone, a thiazolidinedione, can promote the stability of atherosclerotic plaques in fatfed ApoEknockout mice; however, it is unknown whether it can modulate collagen deposition and metabolism in VAPs. The present study was designed to determine the effect of rosiglitazone on collagen deposition and metabolism in the plaques of fatfed ApoEknockout mice. Following 13 weeks of the highfat diet, the mice were randomized into three groups (10 mice/group) and intragastrically administered rosiglitazone, simvastatin and distilled water, respectively, for a further 13 weeks. The category of the collagen present in the plaques was evaluated using the picroSirius red polarization method. Additionally, the protein expression of matrix metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase1 (TIMP1) in the plaques was determined using immunohistochemistry. The results showed that rosiglitazone reduced the lipid to collagen and type to type collagen ratios in the plaques, and these reductions were correlated with the reduction in the plaque MMP9 to TIMP1 ratio. These results suggest that rosiglitazone can modulate collagen deposition and metabolism and promote the stabilization of VAPs.